An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
Study Identifier
UBR-MD-04
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Protocol
Available Language(s): English
Statistical Analysis Plan
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 3
Sex
Female & Male
Age
18 - 76 Years
Protocol Summary
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Study Locations
Location
Status
Location
Radiant Research, Inc.
Birmingham, Alabama, United States, 35211
Status
Not applicable
Location
East Family Physicians PC/Radiant Research, Inc.
Chandler, Arizona, United States, 85224
Status
Not applicable
Location
Desert Clinical Research /Radiant Research, Inc.
Mesa, Arizona, United States, 85213
Status
Not applicable
Location
Xenoscience, Inc.
Phoenix, Arizona, United States, 85004
Status
Not applicable
Location
Central Phoenix Medical Clinic
Phoenix, Arizona, United States, 85020
Status
Not applicable
Location
Radiant Research Inc.
Tucson, Arizona, United States, 85712
Status
Not applicable
Showing {first} - {last} of {total} Results